An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes
Diabetes, Obesity and Metabolism · 2025-08 · 27 (S7) · 14-25
DOI: 10.1111/dom.16616 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 17.07.2025. Verfasst von Geremia B Bolli und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine and Surgery, Perugia University Medical School, Perugia, Italy. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Hypoglycemic Agents, Insulin. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Perugia, MUR -PRIN, Università degli Studi di Perugia.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Advancing therapy in T2DM with injectables, i.e., basal insulin (BI) and GLP‐1 receptor agonists (GLP‐1RAs) is recommended after the failure of oral glucose lowering agents (OGLAs), BI alone, or BI in combination with OGLAs, especially in persons with, or at high risk of atherosclerotic cardiovascular disease (ASCVD). BI and GLP‐1RAs can be administered separately or as fixed‐ratio combinations (FRCs) for daily use (degludec+liraglutide, IDegLira, glargine‐100 + lixisenatide iGlarLixi) or weekly use (icodec+semaglutide, IcoSema). The currently available FRCs IDegLira and iGlarLixi differ in their respective BI as well as GLP‐1RA components. Liraglutide predominantly stimulates glucose‐dependent endogenous insulin secretion in response to nutrient challenges. In contrast, the rapid‐acting lixisenatide primarily delays gastric emptying over a few hours post‐dosing with little or no impact on insulin secretion. IDegLira in DUAL studies and iGlarLixi in LixiLan studies appear to have equivalent lowering effects on HbA1c, although IDegLira achieves a greater reduction in body weight. The weekly FRC IcoSema is superior to weekly insulin icodec (COMBINE 1), to semaglutide (COMBINE 2), and non‐inferior to basal‐bolus insulin therapy (COMBINE 3). Comparison of IcoSema with glargine‐100 is ongoing (COMBINE 4). However, all FRCs are limited by the low GLP‐1RA dose relative to the insulin delivered. Whenever higher GLP‐1RA doses are required (i.e., in obese people), the option of separate dosing of BI and GLP‐1RA with independent titration of each component should be considered.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medicine and Surgery, Perugia University Medical School, Perugia, Italy.
- Centro Diabetologia Asl 2 Umbria 'Centro Storico', Foligno, Italy.
- Department of Medicine and Surgery, Università degli Studi di Milano Bicocca & Policlinico, di Monza, Monza, Italy.
- Endocrine and Metabolic Unit, Royal Adelaide Hospital, University of Adelaide, Adelaide, South Australia, Australia.
- Cardiff University Medical School, Cardiff, UK.
ORCID-Profile: Geremia B Bolli, Carmine G Fanelli, David R Owens
Förderung
- University of Perugia
- MUR -PRIN
- Università degli Studi di Perugia
Zitieren
APA
Bolli, G. B., Porcellati, F., Lucidi, P., Fanelli, C. G., Perseghin, G., Horowitz, M., & Owens, D. R. (2025). An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes. Diabetes, Obesity and Metabolism, 27(S7), 14-25. https://doi.org/10.1111/dom.16616
Vancouver
Bolli GB, Porcellati F, Lucidi P, Fanelli CG, Perseghin G, Horowitz M, et al. An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes. Diabetes, Obesity and Metabolism. 2025;27(S7):14-25. doi:10.1111/dom.16616
BibTeX
@article{Bolli2025,
author = {Bolli, Geremia B and Porcellati, Francesca and Lucidi, Paola and Fanelli, Carmine G and Perseghin, Gianluca and Horowitz, Michael and Owens, David R},
title = {An overview of randomized clinical trials of fixed‐ratio combinations of basal insulin plus GLP ‐ 1RA (injectable therapy): Lessons for advancing therapy in people with type 2 diabetes},
journal = {Diabetes, Obesity and Metabolism},
year = {2025},
volume = {27},
number = {S7},
pages = {14--25},
doi = {10.1111/dom.16616}
}
EUVIMED